SMC approves cabozantinib/nivolumab combination for advanced kidney cancer in Scotland

The Scottish Medicines Consortium (SMC) has approved the use of the combination of cabozantinib (a vascular endothelial growth factor (VEGF) inhibitor) plus nivolumab (an immunotherapy) for use by NHS Scotland for the treatment of untreated people with advanced renal cell carcinoma (RCC). The approval was based on the results from a phase 3 study, which […]

read more

Cabozanitinib in combination with atezolizumab for advanced kidney cancer

This phase Ib study reports the results of a combination of cabozantinib plus atezolizumab in people with advanced clear cell and non–clear cell renal cell carcinoma (RCC). The number and nature of side effects to the 40 mg and 60 mg dose of cabozantinib were similar. Around two thirds of patients reported side effects to […]

read more

Outcomes and side effects after first-line treatment with combination therapies for kidney cancer

This report looked at the results from 4 studies comparing sunitinib with various immunotherapy combinations: nivolumab/ipilimumab, pembrolizumab/axitinib, nivolumab/cabozantinib and pembrolizumab/lenvatinib. Overall survival time, time to when the cancer started growing again and the treatment stopped working (progression-free survival), response to treatment in terms of the cancer getting smaller, and side effects to treatment were all […]

read more

ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up

The use of two medicines together (combination therapies) for previously untreated patients with RCC that has spread (metastatic RCC) is fast becoming standard treatment for these patients. A study called CheckMate-214 showed that a combination of the immune checkpoint inhibitors nivolumab plus ipilimumab helped patients with intermediate or high risk RCC live longer than those […]

read more

ESMO 2021: Belzutifan (MK-6482) plus cabozantinib for advanced clear cell RCC

Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF-2α. This results in several changes in the cancer cells and their surrounding environment that favour tumour growth. The novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), blocks the action of HIF-2α. This […]

read more

ESMO 2021: Alternative treatment schedule for ipilimumab plus nivolumab in first-line treatment of advanced RCC (PRISM)

Ipilimumab plus nivolumab is a standard first-line treatment for patients with intermediate and poor-risk advanced RCC. Serious or life-threatening side effects are relatively common with this combination. The aim of this phase 2 trial (PRISM) was to see if changing the treatment schedule for ipilimumab in combination with nivolumab can improve tolerability of this treatment […]

read more

Camrelizumab plus famitinib in patients with advanced or metastatic kidney cancer

An ongoing phase 2 study of a combination of two new medicines, camrelizumab (an immune checkpoint inhibitor) and famitinib (a novel tyrosine kinase inhibitor that targets a number of kinases) is looking at the safety and effectiveness of this combination in people with advanced or metastatic clear cell renal cell carcinoma (RCC). Previously treated people […]

read more

Health-related quality of life for kidney cancer patients on pembrolizumab/lenvatinib

In this video, Dr Bradley McGregor from the Dana-Farber Cancer Institute in the US and Dr Rana McKay from UC San Diego Health discuss the health-related quality of life of renal cell carcinoma (RCC) patients on the pembrolizumab plus lenvatinib combination. The results from the phase 3 CLEAR/KEYNOTE-581 trial with 1069 RCC patients showed significant […]

read more

FDA approves pembrolizumab plus lenvatinib combination for advanced kidney cancer

The US Food and Drug Administration (FDA) has approved the combination of pembrolizumab, an anti-PD-1 immunotherapy, plus lenvatinib, an oral tyrosine kinase inhibitor, for the first-line treatment of people with advanced renal cell carcinoma (RCC). The approval is based on the results from the phase 3 CLEAR/KEYNOTE-581 trial, in which the combination showed significant improvement […]

read more

Lenvatinib plus pembrolizumab in for untreated and previously treated metastatic kidney cancer

Results from a phase Ib/II study looking at lenvatinib plus pembrolizumab for the treatment of metastatic renal cell carcinoma (RCC) showed that there was a response to treatment and the cancer reduced in size (objective response) in 73% of patients who had not received previous medication for their cancer. There were 143 patients in the […]

read more
Showing 1 to 10 of 152 results
  TOP